BRIDGEWATER, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (NVDL.PK) has signed a preliminary agreement to sell its NovaMist™ technology to SUDA LTD, an Australian publicly held pharmaceutical company.
The proposed transaction includes the sale of NovaDel’s patents and trademarks relating to its NovaMist technology. The sale, as contemplated, does not include the NitroMist® or ZolpiMist™ intellectual property or licenses.
